Navigation Links
NanoSmart™ Pharmaceuticals, Inc., Opens New Headquarters - Begins Development of New Drug Delivery Platform for Cancer
Date:9/7/2011

LAGUNA HILLS, Calif., Sept. 7, 2011 /PRNewswire/ -- NanoSmart™ Pharmaceuticals, Inc., a biopharmaceutical corporation developing novel cancer pharmaceuticals, has moved into its new corporate facility located in Laguna Hills, CA.  The facility provides the administrative and laboratory work space necessary to begin formal development of its initial product pipeline.

"Our new location gives us a physical presence in Orange County, California and allows us to move forward with our strategic development goals," said Dr. Henry Smith, CEO of the company.  "We are excited about the opportunity to develop our initial products and conduct formal, nonclinical studies leading towards our initial regulatory filings," said Dr. Smith.

About the technology:

NanoSmart™ is developing a patented, novel anti-tumor targeting platform based on fully-human autoimmune antibodies.  These antibodies target areas of necrosis found in many different types of cancer.  NanoSmart's drug delivery system represents a versatile platform technology with many advantages, including improved localization of cancer therapeutics leading to increased safety and efficacy.  By combining these antibodies with different cancer drugs, NanoSmart has the potential to develop a very large number of novel biopharmaceutical products.

NanoSmart™ Pharmaceuticals, Inc., is a privately-held company engaged in developing novel methods to treat cancer and other diseases.  The company is focused on using its patented tumor targeting antibodies to develop a variety of biopharmaceuticals to treat many different types of cancer.  This press release may contain forward-looking statements regarding future events.  There can be no assurance that such development efforts will succeed; or that the novel biopharmaceuticals will receive regulatory clearance or achieve commercial success.

For more information contact us at (949) 305-2020
E-mail us at info@nanosmartpharmaceuticals.com
Investor Relations: (310) 951-3282

Please visit our website:  www.nanosmartpharmaceuticals.com


'/>"/>
SOURCE NanoSmart Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Announces Positive Top-Line Results from XIAFLEX® Multi-Cord Study
2. Omthera Pharmaceuticals, Inc. to Present at the Rodman and Renshaw 13th Annual Healthcare Conference
3. Pacira Pharmaceuticals, Inc. Expands EXPAREL™ Commercial Team Infrastructure
4. Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX®
5. Janssen Pharmaceuticals, Inc. Launches Online Tools on PrescribeResponsibly.com
6. Omthera Pharmaceuticals, Inc. Initiates Phase III ESPRIT Trial of Add-on Epanova™ to Statin Therapy in Patients with Hypertriglyceridemia
7. Pacira Pharmaceuticals, Inc. to Present at Wedbush Securities 2011 Life Sciences Management Access Conference
8. Pacira Pharmaceuticals, Inc. Reports Second Quarter 2011 Financial Results
9. K-V Pharmaceutical Company Announces the Completion of the Sale of Nesher Pharmaceuticals, Inc. its Generic Pharmaceutical Business
10. Auxilium Pharmaceuticals, Inc. Announces Promotion of Dr. James P. Tursi to Chief Medical Officer
11. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017  Stealth BioTherapeutics Inc. ( ... treat mitochondrial dysfunction, today announced new additions to its ... as Chief Medical Officer, and Daniel Geffken ... that Jim Carr , Pharm.D. has been promoted ... are pleased to welcome Doug and Daniel to our ...
(Date:1/19/2017)... 19, 2017 James ... & Haematology, 2016;12(Suppl 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ... ... Published recently in a supplement to European ... touchONCOLOGY, an article by James Gilbart ...
(Date:1/19/2017)... , January 19, 2017 ... Otsuka in the Milner Therapeutics Consortium   ... in Cambridge   ... PFE ) as a partner to the ... Consortium, which enables the efficient transfer of materials between ...
Breaking Medicine Technology:
(Date:1/21/2017)... ... , ... In the United States, 20 million women and 10 million men ... feel shame for having struggled with an eating disorder as well as common co-occurring ... in Life After an Eating Disorder” -- to be featured at this year’s iaedp ...
(Date:1/20/2017)... ... ... A new partnership between Goodwill® and Roadie, Inc. aims to make it easier ... couches to dressers and bicycles. Roadie — the national on-the-way delivery network — will ... through February 28th. , “January is an exciting time when resolutions are made ...
(Date:1/20/2017)... ... , ... Doctor C LLC, a company based out of Arizona that focuses ... the marketing and distribution of its product, The Right C. , The Right C ... than traditional vitamin C supplements. At the trade show, Doctor C had the opportunity ...
(Date:1/20/2017)... ... 20, 2017 , ... ATP Science, an Australian-based company focused ... the January ECRM Trade Show in Hilton Head, SC, benefiting from outstanding meetings ... of supplements that keep the body functioning at its peak performance by providing ...
(Date:1/20/2017)... ... January 20, 2017 , ... "TransFlare 4K Mystique comes ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light leak transitions have a ...
Breaking Medicine News(10 mins):